Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -4.88% is 93% above its 5-year average of -65.11%, near the high end of its 5-year range (-154.26%–-4.88%).
As of the fiscal period ended Tuesday, June 30, 2026. 69.11% above its 12-month average of -15.80%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -4.88%.
RETURN ON EQUITY (ROE)
-4.88%
RETURN ON EQUITY (ROE) AVG TTM
-15.80%
RETURN ON EQUITY (ROE) AVG 3Y
-34.04%
RETURN ON EQUITY (ROE) AVG 5Y
-65.11%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+69.11%
CURRENT VS 3Y AVG
+85.66%
CURRENT VS 5Y AVG
+92.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 440 covered companies
CURRENT VS SECTOR MEDIAN
+87.24%
vs the sector median at left
Clover Health Investments, Corp.
Market Cap
$2.43B
Return on Equity (ROE)
-4.88%
TTM Avg
-15.80%
3Y Avg
-34.04%
5Y Avg
-65.11%
Market Cap
$2.43B
Return on Equity (ROE)
-38.17%
TTM Avg
-26.66%
3Y Avg
-25.50%
5Y Avg
23.47%
Market Cap
$2.34B
Return on Equity (ROE)
41.39%
TTM Avg
43.71%
3Y Avg
5.79%
5Y Avg
-18.90%
Market Cap
$2.51B
Return on Equity (ROE)
-56.71%
TTM Avg
-50.91%
3Y Avg
-55.48%
5Y Avg
-35.68%
Market Cap
$2.31B
Return on Equity (ROE)
18.14%
TTM Avg
20.16%
3Y Avg
28.24%
5Y Avg
15.58%
Market Cap
$2.64B
Return on Equity (ROE)
-8.00%
TTM Avg
-28.91%
3Y Avg
-27.68%
5Y Avg
-39.13%
Market Cap
$2.64B
Return on Equity (ROE)
N/A
TTM Avg
9.38%
3Y Avg
9.38%
5Y Avg
9.38%
Market Cap
$2.17B
Return on Equity (ROE)
-42.07%
TTM Avg
-35.11%
3Y Avg
-34.40%
5Y Avg
-30.49%
Market Cap
$2.69B
Return on Equity (ROE)
-56.91%
TTM Avg
-24.13%
3Y Avg
-9.83%
5Y Avg
-11.19%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clover Health Investments, Corp. (CLOV) | $2.43B | -4.88% | -15.80% | -34.04% | -65.11% |
| Disc Medicine, Inc. (IRON)vs › | $2.43B | -38.17% | -26.66% | -25.50% | 23.47% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.34B | 41.39% | 43.71% | 5.79% | -18.90% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.51B | -56.71% | -50.91% | -55.48% | -35.68% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.31B | 18.14% | 20.16% | 28.24% | 15.58% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | -8.00% | -28.91% | -27.68% | -39.13% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.64B | N/A | 9.38% | 9.38% | 9.38% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.17B | -42.07% | -35.11% | -34.40% | -30.49% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | -56.91% | -24.13% | -9.83% | -11.19% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 95.64% | 115.72% | 76.74% | 3213.80% |
ROE
-4.9%
ROA
-2.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -4.88% |
| 2026-03-31 | -16.78% |
| 2025-12-31 | -27.71% |
| 2025-09-30 | -17.11% |
| 2025-06-30 | -12.52% |
| 2025-03-31 | -7.47% |
| 2024-12-31 | -12.61% |
| 2024-09-30 | -26.71% |
| 2024-06-30 | -38.08% |
| 2024-03-31 | -54.68% |
| 2023-12-31 | -74.50% |
| 2023-09-30 | -70.51% |
| 2023-06-30 | -78.94% |
| 2023-03-31 | -104.15% |
| 2022-12-31 | -95.10% |
| 2022-09-30 | -112.90% |
| 2022-06-30 | -94.06% |
| 2022-03-31 | -125.52% |
| 2021-12-31 | -109.78% |
| 2021-09-30 | -129.03% |
| 2021-06-30 | -154.26% |
| 2021-03-31 | -26.78% |
